Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļETON
āļāļ·āđāļāļāļĢāļīāļĐāļąāļEton Pharmaceuticals Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļNov 09, 2018
āļāļĩāļāļĩāđāļBrynjelsen (Sean E)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ31
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļNov 09
āļāļĩāđāļāļĒāļđāđ21925 W Field Pkwy Ste 235
āđāļĄāļ·āļāļDEER PARK
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ60010-7278
āđāļāļĢāļĻāļąāļāļāđ18477877361
āđāļ§āđāļāđāļāļāđhttps://etonpharma.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļETON
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļNov 09, 2018
āļāļĩāļāļĩāđāļBrynjelsen (Sean E)
Mr. Sean E. Brynjelsen
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Mr. Sean E. Brynjelsen
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Mr. Sean E. Brynjelsen
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
Mr. Paul V. Maier
Independent Director
Mr. Paul V. Maier
Independent Director
Mr. Paul V. Maier
Independent Director
Mr. Charles J. (Chuck) Casamento
Mr. Charles J. (Chuck) Casamento
Independent Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. Sean E. Brynjelsen
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Mr. Sean E. Brynjelsen
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Mr. Sean E. Brynjelsen
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board